SUBSCRIBE
SUBSCRIBE

Takeda Pharmaceutical Co. Ltd. Says Lifestyle-Disease Drugs Will Drive Growth

August 19, 2010 | 
1 min read

Bloomberg -- Takeda Pharmaceutical Co. said an unfulfilled need for medicines to treat lifestyle diseases including diabetes will spur sales growth as its biggest drug Actos faces generic competition.

Asia
Takeda
MORE ON THIS TOPIC
Pictured: AstraZeneca building in Gothenburg/iStoc
China
AstraZeneca Names New International Operations Lead Amid Probe on China Exec
December 5, 2024
 · 
3 min read
 · 
Tristan Manalac
GSK's headquarters office building in Poznan, Poland
ADCs
GSK Turns Back to China in Another Potential $1B+ ADC Deal
December 4, 2024
 · 
1 min read
 · 
Kate Goodwin
Chinese flag with digital matrix -Innovation Concept - Digital Tech Wallpaper - 3D illustration
Weight loss
Novo’s Wegovy Launched in China at a Fraction of US Price
November 18, 2024
 · 
1 min read
 · 
Annalee Armstrong
Brain shaped white jigsaw puzzle on blue background. Mental health and problems with memory.
Alzheimer’s disease
Eisai Cuts Fiscal 2024 Guidance for Biogen-Partnered Leqembi as Sales Disappoint Analysts
November 8, 2024
 · 
2 min read
 · 
Tristan Manalac